CSL bids $800 million in vaccine gamble
By Peter Roberts Australian biotechnology and vaccine giant CSL is betting $800 million in the race to secure federal and state funding to establish mRNA vaccine in Australia. The company, which is the fourth most valuable company at $93 billion on the ASX, has outbid a group of smaller firms which are also seeking a…











